secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277468
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma Q3 net loss $0.07/sh; ImmunoScape deal $15M upfront; new CEO
--------------------------------------------------------------------------

- Q3 net loss $7.45M ($0.07 EPS); revenue $2.15M (down 36% YoY); cash $11.7M (down 48% from Dec 2024).
- Collaboration with ImmunoScape: upfront total $15M ($10M in Q4 2025, $5M in Nov 2026) plus 40% equity stake.
- Usman Azam appointed President & CEO effective Sep 29; leadership transition to advance autoimmune asset CUE-401.
- CUE-101+pembrolizumab in HPV+ HNSCC: 50% ORR, 88% 12-month OS, median OS 32.7 months.
- R&D spend $4.8M (down 49% YoY); G&A $4.9M (up 72% YoY) due to severance and professional fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/0001193125-25-277468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/cue-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer